Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A new campaign invites people to chew over the idea of becoming stem cell donors—literally. | A new campaign invites people ...

A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the ...

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

With tariffs looming and pricing policies shifting, life sciences companies may be on the cusp of “pivotal moment,” according ...